NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-08-31
Reading DVA? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Broken: Primary pillar broken — Achieve ~4% annual revenue growth: rev +0.0% vs 3.8%.
DaVita grows revenue about 4% a year as dialysis demand stays steady. Profit margins remain stable with operating income supported by AI tools and center reopenings. Free cash flow improves toward $1.0-$1.25 billion in 2026. The stock trades cheap versus peers with a PE near 20 and strong buyback programs.
Growth could slow if reimbursement rates tighten or regulatory risks rise. Free cash flow may lag the $1 billion target. Rising debt from recent financial obligations could pressure capital allocation. Valuation may stay capped if earnings disappoint.
The price is about 38% below our $375 fair value, reflecting a justified discount. Analysts expect roughly 4% revenue growth, which aligns with our view, but the market undervalues DaVita versus peers.
Breaks if: Free cash flow falls below $1.0 billion in FY26
Breaks if: Operating income declines materially despite AI and center reopenings
Breaks if: YoY revenue growth falls below 3.8% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
DVA represents a durable compounder in the healthcare sector. The current thesis state is stable, with strong recent financial performance but some elevated risks ahead.
The market appears to price DVA as cheap compared to its peers, with a notable expectations gap. This suggests that investors may not fully account for the potential risks and uncertainties in the near term.
Management has shown a commitment to maintaining operating income guidance, with recent results indicating steady growth. However, free cash flow generation is mixed, and there is a low probability of missing guidance, despite a recent history of misses.
The thesis hinges on the performance of the broader healthcare sector and whether key competitors continue to report strong earnings. Additionally, any changes in DVA's guidance could significantly impact market sentiment.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company maintained its operating income guidance. This supports the overall read. However, there are concerns about the stock's recent drop. It beat sales expectations but still fell. This raises questions about future guidance.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: PE rises above 26.6 without earnings growth justification
Overall, DVA's fundamentals show promise, but the elevated risks and sector dynamics warrant close monitoring. Not investment advice.
